Mesenchymal Stem Cell (MSC)

What is MSC?

MSCs (mesenchymal stem cells) are multipotent somatic stem cells isolated from various tissues such as bone marrow, adipose tissue, and umbilical cord. They are generally defined using surface markers such as CD73, CD90, and CD105 positivity, and CD34 and CD45 negativity. In addition to differentiation and tissue repair capacities,Anti-inflammatory and immunomodulatory effects, as well as paracrine effects mediated by humoral factors and Extracellular Vesicles (EVs/exosomes)is an important feature. Clinical applications and research are underway for a wide range of diseases, including acute GVHD, spinal cord injury, inflammatory bowel disease, and ischemic diseases.

Representative examples of MSC

Stemirac injection (Stemirac / bone marrow-derived autologous MSCs)

Stemirac is an autologous bone marrow-derived MSC product approved in Japan for the treatment of spinal cord injury. Following intravenous administration, it is thought to promote the recovery of neurological functions through homing to the injury site, secretion of neuroprotective and axon growth-promoting factors such as BDNF and HGF, and angiogenesis.Representative examples of MSC therapy for spinal cord injuryis positioned as.

TEMCELL HS Inj. (TEMCELL HS Inj. / Bone marrow-derived allogeneic MSCs)

Temcell HS Inj. is an allogeneic bone marrow-derived MSC product approved for pediatric and adult acute GvHD after hematopoietic stem cell transplantation.potent immunomodulatory effects through the suppression of activated T cell proliferation and the regulation of inflammatory cytokines (IFN-γ, TNF-α)is a representative example of MSC therapy whose main mechanism of action is.

Alofisel (Alofisel - darvadstrocel - adipose-derived allogeneic MSCs)

Alofisel is an allogeneic adipose-derived mesenchymal stem cell (ADMSC) product developed for the treatment of complex perianal fistulas associated with Crohn's disease. By local injection around the fistula, it suppresses local immune responses while promoting tissue repair and epithelialization.Representative examples of topically applied MSC treatments distinct from systemic administrationis positioned as.

Key challenges in MSC development

Multifaceted Mechanism of Action (MoA) and the Difficulty of Establishing a "Potency Quantitative Assay"

MSC actions are not based on a single receptor binding, but rather on complex paracrine effects such as cytokine secretion, EV (exosome) release, and cell-cell contact.It is difficult to identify potency markers that reflect the mechanism of action for each indication and to establish functional assays robust enough for quality control (QC).becomes an important development challenge.

pulmonary trapping (PEE) in systemic intravenous administration and low homing/engraftment in target tissues

MSCs have a large cell size, and many are trapped in the pulmonary microvasculature during the first pass after intravenous administration.Quantifying and predicting the kinetics of pulmonary capture, killing, and clearance, as well as the homing dynamics to reach target tissuesHowever, this is a major challenge in MSC cell PK/BD.

functional attenuation and alloimmunogenicity associated with donor-derived differences, tissue sources, and passage

With allogeneic MSCs, in addition to lot-to-lot variations caused by the donor's age and condition, as well as the tissue source such as bone marrow, adipose tissue, or umbilical cord, cellular senescence and functional decline associated with passage pose challenges.Evaluation of functional attenuation caused by mass expansion and alloimmunogenicity/rejection risk associated with induced HLA expressionis also important.

Non-clinical evaluation required for MSC development

Evaluation 1: Establishment of indication-specific "multipotency in vitro functional evaluation systems"

Since it is difficult to predict the clinical efficacy of MSCs based on CD markers alone, it is important to establish a functional evaluation system that correlates with the MoA.Depending on the indication, we comprehensively evaluate T cell proliferation inhibition, macrophage polarization, angiogenesis, secreted factors, and other parameters to construct a highly reproducible Potency Index.is required.

Rating 2: Non-invasive In Vivo Cell Tracking & Biodistribution (BD) Quantification to visualize kinetics after intravenous and local administration

To elucidate the post-administration pharmacokinetics of MSCs, it is important to track clearance from pulmonary trapping and homing/engraftment to target tissues.Combining whole-body imaging such as BLI/PET with tissue-specific quantification by ddPCR/qPCR to evaluate biodistribution, clearance, and ectopic accumulationThis allows us to verify the validity of the administration route and PEE avoidance measures.

Rating 3: Elucidating the mechanism of action in pathological environments: "Drug efficacy in disease model animals & local single-cell/EV secretion analysis"

Since MSCs exert their effects upon receiving licensing through homing and inflammatory responses in pathological microenvironments, evaluation in disease models is important.Analyze the interactions between MSCs and surrounding immune and parenchymal cells, as well as secretory pathways activated in vivo, through scRNA-seq and EV analysis of target tissues.Therefore, we obtain evidence of the mechanism of action and biomarkers.

Rating 4: "Integrated Assessment of Alloimmune Response, Tumorigenicity, and Differentiation Abnormality" to Ensure Safety in Allo-Administration

For allogeneic MSCs, it is important to evaluate alloimmune responses upon repeated administration and long-term safety.Combining MLR/anti-HLA antibody evaluation with long-term tumorigenicity and ectopic tissue formation evaluations in immunodeficient animals to confirm safety upon repeated administration and the Safety Windowis required.

Key points when choosing a contract research organization (CRO) for non-clinical studies

In MSC development, it is important to integrally advance mechanism-of-action-based potency evaluation, pharmacokinetics and biodistribution, efficacy and mechanism of action in disease models, and safety evaluation. Strategic CRO selection capable of integrating diverse evaluation systems and generating data tailored to development objectives is the key to future clinical application and development success.